Pneumococcal conjugate second or third-dose vaccines (PCVc) in Serbia
Serbia: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 91.0% in 2025. ◆ Volatile
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Serbia, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for pneumococcal conjugate second or third-dose vaccines (pcvc) in Serbia is 91.0%, measured in 2025.
That represents a change of up 7.1% on the previous year and up 3.4% over five years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Serbia peaked at 92.0% in 2019 and was at its lowest, 0.0%, in 2008.
Serbia ranks 61st of 194 countries on this measure, in the middle of the range.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Serbia, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 0.0% | — |
| 2012 | 0.0% | — |
| 2013 | 0.0% | — |
| 2014 | 0.0% | — |
| 2015 | 0.0% | — |
| 2016 | 0.0% | — |
| 2017 | 0.0% | — |
| 2018 | 67.0% | — |
| 2019 | 92.0% | +37.3% |
| 2020 | 88.0% | -4.3% |
| 2021 | 89.0% | +1.1% |
| 2022 | 90.0% | +1.1% |
| 2023 | 82.0% | -8.9% |
| 2024 | 85.0% | +3.7% |
| 2025 | 91.0% | +7.1% |
Serbia compared with similar countries
- Serbia's 91.0% is above the median for upper middle income countries, which is 76.0%, 1.2× the median. (57 countries reporting)
- Serbia's 91.0% is above the median for Europe & Central Asia, which is 87.0%, 1.0× the median. (51 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 15.9% | 0.0% | 92.0% | 10 |
| 2020s | 87.5% | 82.0% | 91.0% | 6 |
Countries ranked near Serbia
More health data for Serbia
- Un projection of annual infant deaths, annual growth rate -5.26 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.3584 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,502 deaths per 1,000 people (2090)
- Number of infants who die before age 1 18 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -2.67 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.022 units per person (2025)
- Population ages 00-04, male, annual growth rate -1.67 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Serbia?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Serbia was 91.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Serbia?
- The highest recorded value was 92.0% in 2019.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Serbia?
- The lowest recorded value was 0.0% in 2008.
- How does Serbia rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Serbia ranks 61st out of 194 countries with data for 2025.
- Where does this Serbia data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).